Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Carolina Step Therapy Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Step Therapy Criteria for Selected Prescription Drugs

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs South Carolina Medicare Advantage prescription drug step therapy requirements for the listed affected products. It specifies required trials of formulary alternatives and identifies when continuation of prior therapy is approved.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyStep Therapy Criteria for Selected Prescription Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionDocument the required trial of a formulary or generic alternative before requesting coverage for an affected product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Drug-specific step therapy sections
    2Products affected
    2Required antidepressant trials
    2Required atypical antipsychotic trials
    New starts onlyZonisade step therapy

    Policy Overview

    This South Carolina Medicare Advantage prescription drug step therapy policy applies formulary requirements across dermatologic treatment for actinic keratosis, antidepressant and antipsychotic therapy, long-acting antipsychotic treatment, constipation therapy, Parkinson disease therapy, and epilepsy therapy. Coverage for the affected products is subject to documented use of specified formulary or generic alternatives, with continuation of prior therapy approved where stated.

    Product-Specific Coverage Requirements

    Actinic keratosis

    Coverage of Diclofenac Sodium GEL 3% requires the following step.

    Alternative topical therapy trial: Trial of either topical fluorouracil or topical imiquimod

    Antidepressants

    Coverage of the listed antidepressant products requires the following step.

    Two generic antidepressant trials: Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride2 generic trials

    Approve for continuation of prior therapy.

    Atypical antipsychotics

    Coverage of the listed atypical antipsychotic products requires the following step.

    Two generic atypical antipsychotic trials: Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone2 generic trials

    Approve for continuation of prior therapy.

    Invega Hafyera therapy

    Coverage of Invega Hafyera requires the following step for new starts.

    Prior Invega therapy: Trial of one of the following: Invega Sustenna or Invega Trinza1 prior product trial

    Step applies to new starts only. Approve for continuation of prior therapy.

    Relistor

    Coverage of Relistor requires the following step.

    Alternative therapy trial: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik1 prior product trial

    Rytary

    Coverage of Rytary requires the following step.

    Generic carbidopa/levodopa trial: Trial of one generic carbidopa/levodopa-containing formulation1 prior generic formulation trial

    Rytary

    Rytary approval requires the following step-therapy criterion.

    Rytary step therapy: Trial of one generic carbidopa/levodopa-containing formulation

    Zonisade

    Zonisade approval for new starts requires the following step-therapy criterion.

    Zonisade step therapy: Trial of generic zonisamide capsule

    Step applies to new starts only; approve for continuation of prior therapy.

    Initial Therapy Requirements

    Diclofenac Sodium GEL 3%

    Topical alternative trial: Trial of either topical fluorouracil or topical imiquimod before Diclofenac Sodium GEL 3%

    Emsam, Exxua, and Fetzima

    Generic antidepressant trials: Trial of two generics from the specified formulary antidepressant list2 trials

    Fanapt, Lybalvi, and Secuado

    Generic atypical antipsychotic trials: Trial of two specified oral generic formulary atypical antipsychotic agents

    Continuation Therapy Requirements

    Antidepressants

    Continuation of antidepressant therapy: Approve for continuation of prior therapy after the required generic trials

    Atypical antipsychotics

    Continuation of atypical antipsychotic therapy: Approve for continuation of prior therapy after the required generic trials

    Invega Hafyera

    Continuation of Invega Hafyera therapy: Approve for continuation of prior therapy

    The step applies to new starts only.

    Required Formulary Trials

    StepRequirement
    Step 1Diclofenac Sodium GEL 3%: Trial of either topical fluorouracil or topical imiquimod
    StepRequirement
    Step 1Emsam, Exxua, Exxua Titration Pack, Fetzima, and Fetzima Titration Pack: Trial of two generic formulary antidepressants selected from bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine hydrochloride
    StepRequirement
    Step 1Fanapt, Fanapt Titration Packs A, B, and C, Lybalvi, and Secuado: Trial of two oral generic formulary atypical antipsychotic agents selected from asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone
    StepRequirement
    Step 1Invega Hafyera: Trial of Invega Sustenna or Invega Trinza; applies to new starts only
    StepRequirement
    Step 1Relistor: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik
    StepRequirement
    Step 1Rytary: Trial of one generic carbidopa/levodopa-containing formulation
    StepRequirement
    Step 1Rytary: Trial of one generic carbidopa/levodopa-containing formulation
    StepRequirement
    Step 1Zonisade: Trial of generic zonisamide capsule; applies to new starts only

    Documentation and Authorization Actions

    Step Therapy

    Diclofenac Sodium GEL 3% Prerequisite

    Before approval of Diclofenac Sodium GEL 3% for actinic keratosis, document a trial of either topical fluorouracil or topical imiquimod.

    • Affected product: Diclofenac Sodium GEL 3%
    Step Therapy

    Antidepressant Prerequisite

    For Emsam, Exxua, Exxua Titration Pack, Fetzima, and Fetzima Titration Pack, document trials of two generic formulary antidepressants. Approve for continuation of prior therapy.

    • Qualifying generic alternatives: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine hydrochloride
    • Affected products: Emsam; Exxua; Exxua Titration Pack; Fetzima; Fetzima Titration Pack
    Step Therapy

    Atypical Antipsychotic Prerequisite

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyStep Therapy Criteria for Selected Prescription Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionDocument the required trial of a formulary or generic alternative before requesting coverage for an affected product.
    SourceLink
    On This Page
    Policy OverviewProduct-Specific Coverage RequirementsInitial Therapy RequirementsContinuation Therapy RequirementsRequired Formulary TrialsDocumentation and Authorization Actions
    2 trials

    Invega Hafyera

    Prior Invega product trial: Trial of Invega Sustenna or Invega Trinza1 trial

    Step applies to new starts only.

    Relistor

    Alternative constipation therapy trial: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik1 trial

    Rytary

    Generic carbidopa/levodopa trial: Trial of one generic carbidopa/levodopa-containing formulation1 trial

    Rytary initial therapy

    Initial Rytary therapy requires the following generic trial.

    Rytary initial therapy: Trial of one generic carbidopa/levodopa-containing formulation

    Zonisade initial therapy

    Initial Zonisade therapy requires the following generic trial.

    Zonisade initial therapy: Trial of generic zonisamide capsule

    Step applies to new starts only.

    Zonisade continuation therapy

    Continuation of prior Zonisade therapy is approved.

    Zonisade continuation: Continuation of prior therapy

    The step requirement applies to new starts only.

    For Fanapt, Fanapt Titration Packs A, B, and C, Lybalvi, and Secuado, document trials of two oral generic formulary atypical antipsychotic agents. Approve for continuation of prior therapy.

    • Qualifying generic alternatives: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone
    • Affected products: Fanapt; Fanapt Titration Pack A; Fanapt Titration Pack B; Fanapt Titration Pack C; Lybalvi; Secuado
    Step Therapy

    Invega Hafyera Prerequisite

    For a new start of Invega Hafyera, document a trial of Invega Sustenna or Invega Trinza. This step does not apply to continuation of prior therapy.

    • Affected product: Invega Hafyera
    Step Therapy

    Relistor Prerequisite

    Before approval of Relistor, document a trial of at least one listed alternative laxative or opioid-induced constipation therapy.

    • Qualifying alternatives: lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik
    • Affected product: Relistor
    Step Therapy

    Rytary Prerequisite

    Before approval of Rytary, document a trial of one generic carbidopa/levodopa-containing formulation.

    • Affected product: Rytary
    Step Therapy

    Zonisade Prerequisite

    For a new start of Zonisade, document a trial of generic zonisamide capsules. This step does not apply to continuation of prior therapy.

    • Affected product: Zonisade